
Olympic Steel Inc
Metals & Mining
Olympic Steel Inc (ZEUS) Stock News
The latest ZEUS headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordisk announced that ziltivekimab failed to meet its primary endpoint in the ZEUS phase 3 trial, showing no significant reduction in major adverse cardiovascular events (MACE) despite achieving the expected biological effect of IL-6 pathway inhibition. The drug demonstrated a hazard ratio of 0.99 versus placebo in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation. The company will take a non-cash impairment charge in Q3 2026 but maintains its 2026 profit outlook and plans to continue two additional cardiovascular trials (HERMES and ARTEMIS) expected to report in H1 2027.